Thesis (D.W.S.)--Institute for Worship Studies, 2006. / Abstract and vita. Includes bibliographical references (leaves 133-142).

Thesis (D.D.)--Zahnärztlichen Instituts der Universität Göttigen, 1932.

Thesis (doctoral)--University of Turku, 1980. / Bibliography: p. [48]-51.

Thesis (M.S.)--University of Southern California, 1996. / Includes bibliographical references.

Thesis--Gothenburg. / Cover title. Summary in Russian. Includes bibliographical references (p. 127-131).

Made available in DSpace on 2014-10-09T12:26:16Z (GMT). No. of bitstreams: 0 / Made available in DSpace on 2014-10-09T14:10:14Z (GMT). No. of bitstreams: 1 13710.pdf: 4475928 bytes, checksum: 085de71450d1d624d06f238b8ba1835c (MD5) / Dissertacao (Mestrado Profissionalizante em Lasers em Odontologia) / IPEN/D-MPLO / Instituto de Pesquisas Energeticas e Nucleares - IPEN/CNEN-SP

Submitted by CRISTIAN STATKIEVICZ (c.statkievicz@gmail.com) on 2016-10-15T03:12:53Z No. of bitstreams: 1 DISSERTAÇÃO CRISTIAN VERSÃO FINAL - REPOSITÓRIO.pdf: 7053318 bytes, checksum: 7e3743d0506776749bc5bf1702e95116 (MD5) / Approved for entry into archive by Juliano Benedito Ferreira (julianoferreira@reitoria.unesp.br) on 2016-10-20T18:34:04Z (GMT) No. of bitstreams: 1 statkievicz_c_me_araca.pdf: 7053318 bytes, checksum: 7e3743d0506776749bc5bf1702e95116 (MD5) / Made available in DSpace on 2016-10-20T18:34:04Z (GMT). No. of bitstreams: 1 statkievicz_c_me_araca.pdf: 7053318 bytes, checksum: 7e3743d0506776749bc5bf1702e95116 (MD5) Previous issue date: 2016-08-30 / Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) / OBJETIVOS: Os objetivos do presente estudo foram avaliar o efeito da terapia com laser em baixa intensidade (LLLT) e da terapia fotodinâmica antimicrobiana (aPDT) no processo de reparo alveolar de ratas com os principais fatores de risco para a osteonecrose dos maxilares associada à terapia medicamentosa (ONM-M). MATERIAIS E MÉTODOS: Ratas senis (n=29) foram distribuídas nos grupos: SAL, ZOL, ZOL/LLLT e ZOL/aPDT. Durante sete semanas, a cada dois dias, administrou-se pela via intraperitoneal 0,45ml de NaCl 0,9% (SAL) ou 0,45ml desta mesma solução acrescida de 100μg/Kg de zoledronato (ZOL, ZOL/LLLT e ZOL/aPDT). Decorridas três semanas, realizou-se a exodontia do primeiro molar inferior esquerdo. Nos grupos ZOL/LLLT e ZOL/aPDT as ratas foram submetidas respectivamente a LLLT ou aPDT aos 0, 2 e 4 dias pós exodontia. A eutanásia foi realizada 28 dias após a exodontia. No sítio de extração dental foram realizadas análises: histopatológica do processo de reparação tecidual, histométrica da área de tecido ósseo neoformado (ATO) e imunoistoquímica direcionada para os seguintes biomarcadores: PCNA, BAX, C3C, TNFα, IL-1β, IL-6, HIF-1α, VEGF, CD31, BMP2/4, RUNX-2, OCN, OPG, RANKL e TRAP. RESULTADOS: Os grupos tratados com zoledronato apresentaram maior imunomarcação para OPG e menor imunomarcação para RANKL e TRAP. Em ZOL observou-se áreas de osteonecrose, comprometimento da reparação tecidual, menor ATO, menor imunomarcação para PCNA, HIF-1α, VEGF, CD31, BMP2/4 e OCN, e maior imunomarcação para BAX, C3C, TNFα, IL-1β, IL-6 e RUNX-2 em relação ao SAL. ZOL/LLLT apresentou melhora em alguns parâmetros em relação ao ZOL (ATO, PCNA, TNFα, HIF-1α, VEGF, CD31 e RUNX-2), no entanto, poucos foram os parâmetros que se igualaram ao SAL (PCNA, HIF-1α, VEGF, CD31 e RUNX-2). ZOL/aPDT não apresentou áreas de osteonecrose, o processo de reparação tecidual não diferiu significativamente de SAL, assim como, os seguintes parâmetros ATO, PCNA, BAX, C3C, IL-1β, HIF-1α, VEGF, CD31, RUNX-2 e OCN. CONCLUSÕES: O zoledronato compromete o processo de reparação tecidual do sítio de extração dental em ratas com os principais fatores de risco para a ONM-M. LLLT e aPDT são capazes de melhorar eventos relacionados com o processo de reparo alveolar. A aPDT se mostrou a terapia preventiva mais efetiva para evitar a ONM-M. RELEVÂNCIA CLÍNICA: A aPDT pode se constituir em uma alternativa de terapia preventiva para evitar o desencadeamento de ONM-M pós exodontia. / OBJECTIVES: The aim of this study was to evaluate the effects of Low Level Laser Therapy (LLLT) and antimicrobial photodynamic therapy (aPDT) in the alveolar bone repair in rats with the high risk factors for Medication-Related Osteonecrosis of the Jaw (MRONJ). MATERIALS AND METHODS: Senile rats (n = 29) were distributed into four groups: SAL, ZOL, ZOL/LLLT and ZOL/aPDT. For seven weeks, every two days, 0,45ml 0.9% NaCl (SAL) or 0,45ml of this same solution plus 100μg/kg zoledronate (ZOL, ZOL/LLLT and ZOL/aPDT) were administered intraperitoneally. After three weeks, the first lower left molar was extracted. In ZOL/LLLT and ZOL/aPDT groups, the rats were submitted to LLLT or aPDT therapy at 0, 2 and 4 days after tooth extraction. Euthanasia was performed 28 days after tooth extraction. In dental extraction site was performed the histopathology analysis of the tissue repair, histometric analysis of newly formed bone area (NFB) and immunohistochemistry related to the following biomarkers: PCNA, BAX, C3C, TNFα, IL-1β, IL-6, HIF-1α, VEGF, CD31, BMP2/4, RUNX-2, OCN, OPG, RANKL and TRAP. RESULTS: The groups treated with zoledronate showed higher immunolabeling for OPG and lower immunolabeling for RANKL and TRAP. In ZOL group was observed areas of osteonecrosis, impairment of wound healing, lower ATO, lower immunolabeling for PCNA, HIF-1α, VEGF, CD31, BMP2/4 and OCN, and higher immunolabeling for BAX, C3C, TNFα, IL-1β, IL-6 and RUNX-2 when compared to the SAL group. ZOL/LLLT showed improvement in some parameters regarding to ZOL (ATO, PCNA, TNFα, HIF-1α, VEGF, CD31 and RUNX-2), however, few parameters were similar to the SAL (PCNA, HIF-1α, VEGF, CD31 and RUNX-2). ZOL/aPDT did not present areas of osteonecrosis and the tissue repair did not differ significantly from the SAL groups, as well as the following parameters: PCNA, BAX, C3C, IL-1β, HIF-1α, VEGF, CD31, RUNX-2 and OCN. CONCLUSIONS: The zoledronate compromises the tissue repair of dental extraction site in rats with the high risk factors for MRONJ. LLLT and aPDT were able to improved the events related to wound's healing. The aPDT showed to be the most effective preventive therapy to MRONJ. CLINICAL RELEVANCE: The aPDT can be in a preventive therapy to prevent the triggering of MRONJ after dental extraction. / FAPESP: 2014/02199-1

Made available in DSpace on 2014-10-09T12:26:16Z (GMT). No. of bitstreams: 0 / Made available in DSpace on 2014-10-09T14:10:14Z (GMT). No. of bitstreams: 1 13710.pdf: 4475928 bytes, checksum: 085de71450d1d624d06f238b8ba1835c (MD5) / Dissertacao (Mestrado Profissionalizante em Lasers em Odontologia) / IPEN/D-MPLO / Instituto de Pesquisas Energeticas e Nucleares - IPEN/CNEN-SP

Magister Scientiae Dentium - MSc(Dent) / The purpose of this study was to e8tablish standards (norms), based on three-dimensional stereomicroscopic surveys of the anterior implant-bearing area of severely-resorbed human edentulous mandibles. Such standards could possibly be applied towards the development of a series of transmandibular implants which would have wide applications in a broad spectrum of patients. The sample consisted of forty five severely-resorbed human edentulous mandibles eminating from people of various ages, both genders and several ethnic groups. Only 28 specimens were accompanied by pertinent details about the deceased. Measure~ents were made in the anterior mandibular area bounded by the mental foramina.

Thesis (M.A.)--Boston University, 2008. / The use of bisphosphonate has become more widespread for the treatment of bone metastasis, multiple myeloma, osteoporosis, Paget's disease and other bone malignancies. Osteonecrosis of the jaw (ONJ) has been recently recognized as a possible complication of the use of bisphosphonate therapy. This study includes a review of the literature on the mechanism of action of bisphosphonate and its potential association to the development of osteonecrosis of the jaw. The inhibitory effects of bisphosphonates on osteoclasts and its antiangiogenic properties have been examined as possible mechanisms to induce osteonecrosis of the jaw. The incidence of ONJ in osteoporosis patients receiving bisphosphonate treatment is <1 in 100,000, and in between 1% and 10% in patients with malignancy (Hess et al., 2008). The results of this study suggest a higher incidence of osteonecrosis of the jaw in patients under long term use of nitrogen containing bisphosphonate. The incidence of bisphosphonate associated ONJ in the first 4 to 12 months of therapy was of 1.5% and it increased to 7.7% after 37 to 48 months [Bamias] Additional risk factors include dental extractions, invasive dental procedures and trauma. It is not yet clear, however, if other drugs that affect bone turnover may induce similar complications. This study suggests an association of bisphosphonates to the development of osteonecrosis of the jaw. There is no evidence that bisphosphonates cause osteonecrosis of the jaw. An evaluation of the published data indicates that more research is necessary to understand the relationship of bisphosphonates and osteonecrosis of the jaw.